PT3159329T - Utilização de derivados de ácidos gordos polinsaturados como medicamentos - Google Patents

Utilização de derivados de ácidos gordos polinsaturados como medicamentos

Info

Publication number: PT3159329T
Authority: PT; Portugal
Prior art keywords: hidroxyderivates; medicaments; fatty acids; polyunsaturated fatty; polyunsaturated
Prior art date: 2009-03-16

Application number

PT162011324T

Other languages

English (en)

Original Assignee

Lipopharma Therapeutics S L

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-03-16

Filing date

2010-03-15

Publication date

2020-11-13

2010-03-15 Application filed by Lipopharma Therapeutics S L filed Critical Lipopharma Therapeutics S L

2020-11-13 Publication of PT3159329T publication Critical patent/PT3159329T/pt

Links

239000003814 drug Substances 0.000 title 1
235000020777 polyunsaturated fatty acids Nutrition 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

PT162011324T 2009-03-16 2010-03-15 Utilização de derivados de ácidos gordos polinsaturados como medicamentos PT3159329T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
ES200900725A ES2345241B1 (es)	2009-03-16	2009-03-16	Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.

Publications (1)

Publication Number	Publication Date
PT3159329T true PT3159329T (pt)	2020-11-13

Family

ID=42673244

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT162011324T PT3159329T (pt)	2009-03-16	2010-03-15	Utilização de derivados de ácidos gordos polinsaturados como medicamentos
PT107531584T PT2409963T (pt)	2009-03-16	2010-03-15	Utilização de derivados de ácidos gordos polinsaturados como medicamentos

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT107531584T PT2409963T (pt)	2009-03-16	2010-03-15	Utilização de derivados de ácidos gordos polinsaturados como medicamentos

Country Status (19)

Country	Link
US (7)	US9161928B2 (pt)
EP (2)	EP2409963B1 (pt)
JP (1)	JP5904592B2 (pt)
KR (4)	KR20190018754A (pt)
CN (4)	CN102356057A (pt)
AU (6)	AU2010224749B2 (pt)
BR (1)	BRPI1009860A8 (pt)
CA (1)	CA2754963C (pt)
CL (1)	CL2011002268A1 (pt)
DK (2)	DK2409963T3 (pt)
ES (3)	ES2345241B1 (pt)
HK (1)	HK1232207A1 (pt)
HU (2)	HUE051850T2 (pt)
MX (1)	MX2011009614A (pt)
PL (1)	PL2409963T3 (pt)
PT (2)	PT3159329T (pt)
RU (1)	RU2513995C2 (pt)
SI (1)	SI3159329T1 (pt)
WO (1)	WO2010106211A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2345241B1 (es)	2009-03-16	2011-09-08	Lipopharma Therapeutics	Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
US10052299B2 (en)	2009-10-30	2018-08-21	Retrotope, Inc.	Alleviating oxidative stress disorders with PUFA derivatives
EP2701698B1 (en)	2011-04-26	2020-12-23	Retrotope, Inc.	Disorders implicating pufa oxidation
AU2012249918B2 (en)	2011-04-26	2017-06-15	Biojiva Llc	Impaired energy processing disorders and mitochondrial deficiency
DK2701697T3 (da)	2011-04-26	2020-06-29	Retrotope Inc	Oxidative nethindesygdomme
KR102111997B1 (ko)	2011-04-26	2020-05-18	레트로토프 인코포레이티드	Ｐｕｆａ와 관련된 신경퇴행성 질환 및 근육 질환
ES2401629B1 (es) *	2011-10-07	2014-03-04	Universitat De Les Illes Balears	Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.
RU2679443C2 (ru)	2014-10-21	2019-02-11	Университат Де Лес Ильес Балеарс	Способ синтеза гидрокситриглицеридов и их применение для профилактики и лечения заболеваний
JP6569919B2 (ja) *	2015-03-06	2019-09-04	国立大学法人新潟大学	レビー小体型認知症のバイオマーカー
WO2017091279A1 (en)	2015-11-23	2017-06-01	Retrotope, Inc.	Site-specific isotopic labeling of 1, 4-diene systems
GB201521085D0 (en) *	2015-11-30	2016-01-13	Biozep As	Use
EP4234035A3 (en)	2017-05-16	2023-11-15	Ability Pharmaceuticals S.A.	A pharmaceutical combination for the treatment of a cancer
US10596165B2 (en)	2018-02-12	2020-03-24	resTORbio, Inc.	Combination therapies
SG11202012447YA (en)	2018-06-15	2021-01-28	Navitor Pharm Inc	Rapamycin analogs and uses thereof
TW202134234A (zh)	2019-12-05	2021-09-16	美商奈維特製藥公司	雷帕黴素類似物及其用途
ES2846824B2 (es) *	2020-01-29	2022-01-19	Univ Illes Balears	Profarmacos de acidos grasos poliinsaturados y usos medicos de los mismos
JP2023518640A (ja) *	2020-01-29	2023-05-08	ウニバシタットデレスイレスバレアース	αヒドロキシル化脂肪酸代謝産物、その医学的使用およびバイオマーカーとしての使用
MX2022008623A (es)	2020-02-10	2022-08-08	Ability Pharmaceuticals S L	Una combinacion farmaceutica para el tratamiento de un cancer.
WO2021168311A1 (en)	2020-02-21	2021-08-26	Retrotope, Inc.	Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8717816D0 (en)	1987-07-28	1987-09-03	Manchester Inst Science Tech	Fabric testing apparatus
GB2218984B (en) *	1988-05-27	1992-09-23	Renafield Limited	Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses
JPH05974A (ja) *	1991-06-21	1993-01-08	Sagami Chem Res Center	ハロゲン化不飽和アルキル化合物及びその前駆体
ES2161146B1 (es) *	1999-06-29	2002-07-01	Consejo Superior Investigacion	Compuestos antimicrobianos, uso y metodo para inducir resistencia a infecciones de bacterias en plantas.
US6344574B1 (en)	2000-07-20	2002-02-05	The United States Of America As Represented By The Secretary Of Agriculture	Solvent fractionation of chicken fat for making lipid compositions enriched in unsaturated fatty acid-containing triacylglycerols
DE10106660A1 (de) *	2001-02-12	2002-08-29	Celanese Ventures Gmbh	Verfahren zur Herstellung von gamma-Linolensäure aus einer Ciliaten-Kultur durch Zusatz geeigneter Vorläufermoleküle zu dem Kulturmedium
ES2186576B1 (es) *	2001-10-11	2004-09-16	Universitat De Les Illes Balears	Acido 2-hidroxioleico para utilizar como medicamento.
WO2003084305A2 (en) *	2002-04-01	2003-10-16	University Of Southern California	Trihydroxy polyunsaturated eicosanoids
US7135575B2 (en) *	2003-03-03	2006-11-14	Array Biopharma, Inc.	P38 inhibitors and methods of use thereof
KR20070090928A (ko) *	2004-11-19	2007-09-06	마텍 바이오싸이언스스 코포레이션	장쇄 다가불포화 지방산으로부터의 옥시리핀, 및 이의 제조방법 및 사용 방법
GB0428384D0 (en)	2004-12-24	2005-02-02	Sla Pharma Ag	Eicosapentaenoic acid
US8324276B2 (en) *	2005-01-24	2012-12-04	Pronova Biopharma Norge As	Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
CN101213281B (zh) *	2005-05-04	2013-03-13	普罗诺瓦生物医药挪威公司	新的dha衍生物及其作为药物的用途
AU2006242914B2 (en) *	2005-05-04	2012-02-02	Pronova Biopharma Norge As	New DHA derivatives and their use as medicaments
US8059805B2 (en) *	2005-06-30	2011-11-15	Emc Corporation	Enhanced services provided using communication redirection and processing
CN103211807A (zh)	2005-07-08	2013-07-24	Dsmip资产公司	用于治疗痴呆和前痴呆相关病症的多不饱和脂肪酸
EP1772146A1 (en) *	2005-10-03	2007-04-11	Neuropharma, S.A.	Polyunsaturated fatty acids as bace inhibitors
WO2007058523A1 (en) *	2005-11-17	2007-05-24	N.V. Nutricia	Composition with docosapentaenoic acid
DK1800675T3 (da) *	2005-12-23	2011-09-05	Nutricia Nv	Sammensætninger omfattende polyumættede fedtsyrer, proteiner og mangan og/eller molybdæn og nucleosider/nucleotider til behandling af demens
JP2010508262A (ja)	2006-11-01	2010-03-18	プロノヴァバイオファーマノルゲアーエス	組成物
CN101535238A (zh) *	2006-11-01	2009-09-16	普罗诺瓦生物医药挪威公司	作为过氧化物酶体增生物激活受体(PPAR)的活化剂或调节剂的α-取代的ω-3脂质
WO2008053340A1 (en) *	2006-11-03	2008-05-08	Pronova Biopharma Norge As	A combination product comprising at least one lipid substituted in the alpha position and at least one hypoglycemic agent
US20080234377A1 (en) *	2007-03-23	2008-09-25	Martek Biosciences Corporation	Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions
ES2345241B1 (es) *	2009-03-16	2011-09-08	Lipopharma Therapeutics	Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
ES2401629B1 (es) *	2011-10-07	2014-03-04	Universitat De Les Illes Balears	Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.

2009
- 2009-03-16 ES ES200900725A patent/ES2345241B1/es active Active
2010
- 2010-03-15 ES ES10753158.4T patent/ES2613606T3/es active Active
- 2010-03-15 KR KR1020197004239A patent/KR20190018754A/ko active Search and Examination
- 2010-03-15 DK DK10753158.4T patent/DK2409963T3/en active
- 2010-03-15 PT PT162011324T patent/PT3159329T/pt unknown
- 2010-03-15 CA CA2754963A patent/CA2754963C/en active Active
- 2010-03-15 HU HUE16201132A patent/HUE051850T2/hu unknown
- 2010-03-15 KR KR1020207005917A patent/KR102233102B1/ko active IP Right Grant
- 2010-03-15 CN CN2010800119398A patent/CN102356057A/zh active Pending
- 2010-03-15 US US13/257,128 patent/US9161928B2/en active Active
- 2010-03-15 EP EP10753158.4A patent/EP2409963B1/en active Active
- 2010-03-15 PL PL10753158T patent/PL2409963T3/pl unknown
- 2010-03-15 RU RU2011141850/04A patent/RU2513995C2/ru active
- 2010-03-15 JP JP2012500281A patent/JP5904592B2/ja active Active
- 2010-03-15 CN CN201610773030.5A patent/CN106420686B/zh active Active
- 2010-03-15 BR BRPI1009860A patent/BRPI1009860A8/pt not_active Application Discontinuation
- 2010-03-15 HU HUE10753158A patent/HUE032027T2/en unknown
- 2010-03-15 ES ES16201132T patent/ES2820025T3/es active Active
- 2010-03-15 KR KR1020117024210A patent/KR101833772B1/ko active IP Right Grant
- 2010-03-15 EP EP16201132.4A patent/EP3159329B1/en active Active
- 2010-03-15 KR KR1020187005245A patent/KR20180021931A/ko not_active Application Discontinuation
- 2010-03-15 SI SI201032041T patent/SI3159329T1/sl unknown
- 2010-03-15 PT PT107531584T patent/PT2409963T/pt unknown
- 2010-03-15 WO PCT/ES2010/070153 patent/WO2010106211A1/es active Application Filing
- 2010-03-15 DK DK16201132.4T patent/DK3159329T3/da active
- 2010-03-15 MX MX2011009614A patent/MX2011009614A/es active IP Right Grant
- 2010-03-15 CN CN201910095352.2A patent/CN109999018A/zh active Pending
- 2010-03-15 AU AU2010224749A patent/AU2010224749B2/en not_active Revoked
- 2010-03-15 CN CN201610773061.0A patent/CN106349058B/zh active Active
2011
- 2011-09-13 CL CL2011002268A patent/CL2011002268A1/es unknown
2015
- 2015-09-29 US US14/869,045 patent/US9763906B2/en active Active
- 2015-09-29 US US14/869,080 patent/US9763907B2/en active Active
2016
- 2016-07-13 US US15/209,540 patent/US9907772B2/en active Active
- 2016-10-07 AU AU2016238970A patent/AU2016238970B2/en not_active Revoked
2017
- 2017-06-02 HK HK17105487.0A patent/HK1232207A1/zh unknown
- 2017-08-22 US US15/683,379 patent/US10201515B2/en active Active
2018
- 2018-06-05 AU AU2018203976A patent/AU2018203976B2/en not_active Expired - Fee Related
- 2018-12-18 US US16/224,262 patent/US20190365690A1/en not_active Abandoned
2019
- 2019-09-06 AU AU2019226257A patent/AU2019226257B2/en active Active
2020
- 2020-04-22 US US16/855,463 patent/US11253497B2/en active Active
- 2020-07-13 AU AU2020205213A patent/AU2020205213B2/en active Active
- 2020-07-13 AU AU2020205214A patent/AU2020205214B2/en active Active

Also Published As

Publication number	Publication date
PT2409963T (pt)	2017-02-15
US9763906B2 (en)	2017-09-19
WO2010106211A1 (es)	2010-09-23
JP5904592B2 (ja)	2016-04-13
SI3159329T1 (sl)	2021-01-29
US20120108550A1 (en)	2012-05-03
US9161928B2 (en)	2015-10-20
AU2020205213B2 (en)	2021-02-25
ES2820025T3 (es)	2021-04-19
AU2016238970B2 (en)	2018-03-08
US9907772B2 (en)	2018-03-06
EP3159329B1 (en)	2020-08-12
US11253497B2 (en)	2022-02-22
AU2019226257A1 (en)	2019-09-26
BRPI1009860A2 (pt)	2016-03-08
CN106349058A (zh)	2017-01-25
US20180085332A1 (en)	2018-03-29
RU2513995C2 (ru)	2014-04-27
HUE032027T2 (en)	2017-08-28
ES2345241A1 (es)	2010-09-17
RU2011141850A (ru)	2013-04-27
DK2409963T3 (en)	2017-02-27
EP2409963A4 (en)	2013-10-02
PL2409963T3 (pl)	2017-05-31
AU2020205214A1 (en)	2020-07-30
KR20110137365A (ko)	2011-12-22
AU2019226257B2 (en)	2020-05-07
HUE051850T2 (hu)	2021-03-29
KR102233102B1 (ko)	2021-03-26
EP3159329A1 (en)	2017-04-26
AU2018203976B2 (en)	2019-06-06
AU2016238970A1 (en)	2016-11-03
DK3159329T3 (da)	2020-11-09
US10201515B2 (en)	2019-02-12
KR20200024953A (ko)	2020-03-09
EP2409963B1 (en)	2017-01-04
BRPI1009860A8 (pt)	2019-12-17
ES2613606T3 (es)	2017-05-24
EP2409963A1 (en)	2012-01-25
CN106420686A (zh)	2017-02-22
US20190365690A1 (en)	2019-12-05
MX2011009614A (es)	2012-01-20
AU2020205213A1 (en)	2020-07-30
KR20180021931A (ko)	2018-03-05
AU2010224749B2 (en)	2016-07-07
CN109999018A (zh)	2019-07-12
ES2345241B1 (es)	2011-09-08
US20200352891A1 (en)	2020-11-12
KR101833772B1 (ko)	2018-03-02
CA2754963C (en)	2022-02-08
CN106349058B (zh)	2020-01-14
CA2754963A1 (en)	2010-09-23
AU2020205214B2 (en)	2021-02-18
US20170035720A1 (en)	2017-02-09
AU2018203976A1 (en)	2018-06-21
KR20190018754A (ko)	2019-02-25
CN102356057A (zh)	2012-02-15
JP2012520344A (ja)	2012-09-06
US20160158181A1 (en)	2016-06-09
US9763907B2 (en)	2017-09-19
HK1232207A1 (zh)	2018-01-05
CN106420686B (zh)	2020-05-22
US20160158180A1 (en)	2016-06-09
AU2010224749A1 (en)	2011-10-13
CL2011002268A1 (es)	2012-01-27

Publication	Publication Date	Title
HK1232207A1 (zh)	2018-01-05	多不飽和脂肪酸的衍生物作為藥物的用途
EP2498602A4 (en)	2014-05-21	STABILIZED FORMULATIONS FROM FATTY ACIDS
EP2459189A4 (en)	2013-01-16	FATTY ACIDS AS ANTI-INFLAMMATORY ACTIVE SUBSTANCES
EP2425007A4 (en)	2013-01-02	PREPARATION OF FATTY ACID ESTERS
IL212112A0 (en)	2011-06-30	Production of modifird fatty acids in plants
EP2521447A4 (en)	2014-04-30	FATTY FATTY ACID DERIVATIVES AND USES THEREOF
EP2483233A4 (en)	2013-08-14	HETEROATOMA CONTAINING SUBSTITUTED FATTY ACIDS
ZA201104036B (en)	2012-03-28	Fatty acids for use as a medicament
IL232748A0 (en)	2014-07-31	Preparations including fatty acids with 20 carbons and methods for their preparation and use
IL214887A0 (en)	2011-11-30	Fatty acid monoglyceride compositions
IL213354A (en)	2017-06-29	Alpha-monoclonal fatty acid alpha history for use as a drug
PT2528889T (pt)	2019-01-28	Processo para preparar e purificar ácidos gordos
GB201304550D0 (en)	2013-04-24	Conjugates of polyunsaturated fatty acids and amine-containing compounds and uses thereof
EP2726086A4 (en)	2015-04-29	COMPOSITIONS CONTAINING FATTY NITROACIDS
IL219958A0 (en)	2012-07-31	Omega-3 fatty acid enriched meat compositions
HK1185806A1 (zh)	2014-02-28	含有多不飽和脂肪酸的組合物
GB0904300D0 (en)	2009-04-22	Essential fatty acid compounds
AU2010903057A0 (en)	2010-07-22	Acetylenation of fatty acids
GB201021862D0 (en)	2011-02-02	Improvements in the manufacture of fatty acids